

1   **Inflammasome-related markers at the ICU admission are**  
2   **not associated with outcome in the critically ill COVID-**  
3   **19 patients.**

4   Barbara Adamik<sup>1</sup> [barbara.adamik@umed.wroc.pl](mailto:barbara.adamik@umed.wroc.pl)  
5   Magdalena Ambrożek-Latecka<sup>2</sup> [magdalena.ambrozek-latecka@cmkp.edu.pl](mailto:magdalena.ambrozek-latecka@cmkp.edu.pl)  
6   Barbara Dragan<sup>1</sup> [barbara.dragan@umed.wroc.pl](mailto:barbara.dragan@umed.wroc.pl)  
7   Aldona Jeznach<sup>3</sup> [aldona.jeznach@cmkp.edu.pl](mailto:aldona.jeznach@cmkp.edu.pl)  
9   Jakub Śmiechowicz<sup>1</sup> [jakub.smiechowicz@umed.wroc.pl](mailto:jakub.smiechowicz@umed.wroc.pl)  
10   Waldemar Goździk<sup>1</sup> [waldemar.gozdzik@umed.wroc.pl](mailto:waldemar.gozdzik@umed.wroc.pl)  
12   Tomasz Skirecki<sup>2,3\*</sup> [tskirecki@cmkp.edu.pl](mailto:tskirecki@cmkp.edu.pl)

13

14   <sup>1</sup> Department of the Anaesthesiology and Intensive Therapy, Wroclaw Medical University,  
15   Wroclaw, Poland;

16   <sup>2</sup>Department of Clinical Cytology, Centre of Postgraduate Medical Education, Warsaw, Poland

17   <sup>3</sup>Laboratory of Flow Cytometry, Centre of Postgraduate Medical Education, Warsaw, Poland

18   Correspondence: Tomasz Skirecki

19   Laboratory of Flow Cytometry

20   Centre of Postgraduate Medical Education

21   Marymoncka 99/103

22   01-813 Warsaw

23   Poland

24   Tel +48 22 5693830

25   Fax +48 22 5693700

26   Email [tskirecki@cmkp.edu.pl](mailto:tskirecki@cmkp.edu.pl)

27

28

29     **Abstract:**

30     **Purpose:** Development of targeted biological therapies for COVID-19 requires reliable  
31     biomarkers that could help indicate the responding patients. Hyperactivation of the inflammasome  
32     by SARS-CoV2 virus is hypothesized to contribute to severe course of the COVID-19 disease.  
33     Therefore, we aimed to evaluate the prognostic value of several inflammasome-related cytokines  
34     and proteins at the admission to the intensive care unit (ICU).

35     **Patients and methods:** Plasma samples were obtained from 45 critically ill COVID-19 patients  
36     and from 10 patients any without any signs of infection (TBI, traumatic brain injury) on admission  
37     to the ICU. The concentration of IL-1 $\alpha$ , IL-1 $\beta$ , IL-18, IL-1RA, galectin-1, ASC, LDH, ferritin, and  
38     gasdermin D were analyzed. A novel cell-free caspase-1 plasma assay was developed by  
39     inhibitor-based immunoprecipitation followed by Western Blot. Demographic and clinical  
40     characteristics were recorded.

41     **Results:** In-hospital mortality in COVID-19 patients reached 62%. Galectin-1 was 1.8-fold lower  
42     in COVID-19 than in TBI patients (17101.84 vs. 30764.20 pg/ml, p=0.007), but other  
43     inflammasome-related biomarkers were at similar concentrations. Patients with SOFA score of >9  
44     on admission who were at high risk of death had significantly higher galectin-1 but lower IL-1RA  
45     in comparison to low-risk patients (25551.3 pg/ml vs 16302.7 pg/ml, p=0.014; 14.5 pg/ml vs 39.4  
46     pg/ml, p=0.04, respectively). Statistically significant correlations were observed between: IL-1 $\alpha$   
47     and platelets ( $r=-0.37$ ), IL-1 $\beta$  and platelets ( $r=-0.36$ ), ferritin and INR ( $r=0.39$ ). Activated caspase-  
48     1 p35 was detectable in 12/22 COVID-19 patients but in none of the TBI patients. Its presence  
49     was related with higher fibrinogen and lower D-dimers. Moreover, the densitometric analysis  
50     showed a significantly higher amount of p35 in patients with SOFA> 9.

51     **Conclusion:** Our results indicate that the systemic markers of activation of the inflammasome in  
52     critically ill COVID-19 patients is not directly related with outcome. Therefore, potential  
53     interventions aimed at the inflammasome pathway in this group of patients may be of limited  
54     effectiveness and should be biomarker-guided.

55     **Keywords:** SARS-CoV2, biomarker, inflammation, caspase-1, critical care, interleukin-1

## 56 Introduction

57 Infection with the respiratory SARS-CoV2 virus causes the coronavirus disease 2019  
58 (COVID-19) which ranges from asymptomatic infection through mild and severe disease  
59 (pneumonia) to critical disease which has a form of the acute respiratory distress syndrome  
60 (ARDS) or sepsis and septic shock<sup>1</sup>. This range of severity is reflected by the mortality ranges  
61 which reaches approx. 40% in critically ill patients<sup>2</sup>. Although other coronavirues can infect  
62 humans, the COVID-19 is characterized by unique pathogenesis making it a distinct disease<sup>3</sup>.  
63 Aside from respiratory support, the only widely accepted treatment for COVID-19 is  
64 dexamethasone and recently tocilizumab<sup>1</sup>.

65 There is an urgent need to develop efficient therapies for COVID-19 and it becomes  
66 apparent that as in the case of bacterial sepsis, a biomarker-guided personalized approach is a  
67 prerequisite for successful biological therapies<sup>4</sup>. Since early pandemics we among others have  
68 proposed that the unbalanced inflammasome signaling may be a key process in the pathogenesis  
69 of COVID-19<sup>5,6</sup>. Briefly, inflammasomes are multiprotein complexes activated by various stimuli  
70 such as dsDNA (Absent in Melanoma, AIM2), potassium efflux and reactive oxygen species (NLR  
71 Family Pyrin Domain Containing 3, NLRP3)<sup>7</sup>. Upon activation, the receptor proteins oligomerize  
72 and recruit adaptor proteins (apoptosis-associated speck-like protein, ASC) and pro-caspase-1.  
73 Then pro-caspase-1 undergoes autoproteolysis to its active form which then can cleave pro-  
74 interleukin-1 $\alpha$ ,  $\beta$ , -18 and gasdermin D (GSDMD). N-terminal GSDMD can form pores in the cell  
75 membrane which leads to the release of the cleaved cytokines as well as other molecules (such  
76 as lactate dehydrogenase; alarmins) and lytic cell death called pyroptosis<sup>7</sup>. Indeed, it has been  
77 demonstrated that the inflammasome is activated in the lungs of COVID-19 patients<sup>8,9</sup> and can be  
78 activated in the circulating monocytes<sup>10</sup>. However, the status of inflammasome reactivity in the  
79 blood myeloid cells appears complexed<sup>11</sup>. Although some studies showed an increase in  
80 concentrations of pro-inflammatory cytokines with increasing severity of COVID-19<sup>12</sup>, there is a  
81 limited number of studies focused on critically ill COVID-19 patients who are at the highest risk of  
82 death. Nevertheless, there are ongoing clinical trials with direct (Dapansutile, Colchicine)

83 inflammasome inhibitors and indirect (Disulfiram, a GSDMD inhibitor). Also, recently two studies  
84 on the IL-1R antagonist in COVID-19 were published with opposite results<sup>13,14</sup>.

85 In this study, we aimed to evaluate the prognostic utility of selected plasma proteins  
86 related to inflammasome activation in critically ill COVID-19 patients. Considering the high  
87 mortality and lack of effective therapies we focused on the critically ill COVID-19 patients at the  
88 admission to intensive care unit (ICU). We hypothesized that biomarkers of good accuracy could  
89 serve to guide immunomodulatory therapies targeting the inflammasomes.

90

## 91 **Material and methods**

### 92 ***Patients***

93 We have prospectively collected samples from 45 patients with critical COVID-19 at the  
94 admission to ICU of the Wroclaw Medical University. Critical COVID-19 was defined according to  
95 COVID-19 treatment guidelines<sup>1</sup>. Briefly, the patients filled criteria for acute respiratory distress  
96 syndrome (ARDS), sepsis, septic shock, and required introduction of life-sustaining therapies<sup>1</sup>.  
97 SARS-CoV2 infection was confirmed by real-time reverse-transcriptase polymerase chain  
98 reaction (RT-PCR) assay of nasal or pharyngeal swab probes. All patients were treated according  
99 to the WHO guidelines<sup>1</sup>. All patients were administered intravenous dexamethasone at a dose of  
100 6 mg per day. The study protocol complies with the 1975 Declaration of Helsinki as revised in  
101 1983. The Wroclaw Medical University Bioethics Committee approved this study (consent No.  
102 394/2021). The Committee also approved the collection of plasma from the traumatic brain injury  
103 (TBI) (consent No.KB-391/2015). Written informed consent was obtained from the patient or a  
104 legally authorized representative. Blood samples collected from patients with TBI were used to  
105 compare markers of inflammasome activation between cases with SARS-CoV2 infection (COVID-  
106 19 group) and cases without any signs of infection (TBI group). The clinical status of the patients  
107 was determined with the Acute Physiology and Chronic Health Evaluation (APACHE) II score and  
108 Sequential Organ Failure Assessment (SOFA) score on admission to the ICU. The APACHE II

109 score it is routinely used as a prediction tool for ICU patients and includes 12 physiological  
110 variables (the fraction of inspired oxygen, partial pressure of oxygen, body temperature, mean  
111 arterial pressure, blood pH, heart rate, respiratory rate, serum sodium, serum potassium, serum  
112 creatinine, hematocrit, white blood cell count, and the Glasgow Coma Scale) and 2 disease-  
113 related variables (the history of severe organ failure or immunocompromised and the type of ICU  
114 admission). The SOFA score is routinely used in the ICU for monitoring the severity of patient's  
115 clinical condition based on the status of the following systems: respiratory ( $\text{PaO}_2/\text{FiO}_2$  index),  
116 cardiovascular (mean arterial pressure and the dose of vasopressors), hepatic (bilirubin level),  
117 coagulation (platelets level), renal (creatinine level/urine output), and neurological (Glasgow coma  
118 scale).

119

## 120 **Cytokine analysis**

121 The blood samples were collected via routinely inserted arterial cannula. 2.7 ml of peripheral  
122 blood was collected into 0.109 M sodium citrate containing tubes (BD Vacutainer, BD, NJ, USA).  
123 Plasma was collected after centrifugation at 2000 x g for 10 minutes and stored at -70°C. IL-1 $\alpha$ ,  
124 IL-1 $\beta$ , IL-18, IL-1RA and galectin-1 concentrations were analyzed by Milliplex Human Multiplex  
125 Assay (Merck, Germany) using the Magpix System. ACS protein was analyzed using the  
126 commercially available ELISA kit (Cusabio Technology, TX, USA). Human GSDMD was analyzed  
127 using commercial ELISA kit (Abclonal, MA, USA). Other analytes were measured at the certified  
128 hospital clinical laboratory.

129

## 130 **Caspase-1 immunoprecipitation**

131 Equal volumes of plasma (200  $\mu\text{l}$ ) from Controls (TBI) and COVID-19 patients were treated with  
132 50  $\mu\text{M}$  Biotin-FAD-FMK (SantaCruz Biotechnology, CA, USA) with gentle rotation at 4°C  
133 overnight. Then, 10  $\mu\text{l}$  of Streptavidin Sepharose Bead Conjugate (Cell Signalling Technology,  
134 MA, USA) was added to plasma samples and incubated for 5h with gentle rotation at 4°C. The  
135 biotin-streptavidin bead complexes were centrifuged for 5 min at 2300 x g and washed 5 times

136 using 1 x Ripa Lysis buffer (Millipore) supplemented with Protease Inhibitor Cocktail (Millipore)  
137 and 1 mM PMSF. Pellet samples were suspended in 4 x Laemmli buffer and boiled for 3 min in  
138 94°C. For detection of the active forms' caspase-1 the pulled down immunocomplexes were  
139 separated in 15 % SDS - PAGE gels following by wet electrotransfer onto PVDF membranes.  
140 Non-specific bindings were blocked in TBS-T with 5 % non – fat milk for 1 h in room temperature.  
141 Membranes were incubated with anti – Caspase-1 (cleaved 297; 1:1000 dilution; GenTex)  
142 overnight at 4°C. Rabbit polyclonal antibody (1: 10000 dilution; Vector Laboratories, Inc.) was  
143 used to detect primary antibody. Signals were visualized by WesternBright® ECL HRP substrate  
144 (Advansta) using UVITEC gel documentation system. Densitometric analysis was done by  
145 GelAnalyzer 19.1.

146

## 147 ***Statistical analysis***

148 Normality of data was tested using the Shapiro-Wilk test. Continuous variables are expressed as  
149 median values and interquartile ranges whereas categorical variables are presented as  
150 frequencies with percentages. Categorical variables were compared using the Fisher's exact test.  
151 Continuous variables were compared using the Mann-Whitney test. Receiver operating  
152 characteristic (ROC) curves were constructed to calculate area under the curve (AUC) of the  
153 investigated parameters. The cut-off values were indicated using the Youden's index method.  
154 Correlations between variables were tested using the Spearman's test. Logistic regression  
155 analysis was performed to test the relationship between biomarkers and the risk of death or  
156 development of secondary infections. Statistica 13.1 software was used for calculations and  
157 GraphpadPrism 9.0 was used to create graphs. Statistical significance was determined as p <  
158 0.05.

## 159 **Results**

### 160 ***Clinical characteristics of the patient's population***

161 We have enrolled forty-five critically ill COVID-19 patients with RT-PCR confirmed SARS-CoV2  
162 infection. The clinical and demographic characteristic of the group is presented in **Tab. 1**. This  
163 group included 24 males (53%) and 21 females and the median age was 58 years (IQ: 43-68). At  
164 admission, the patients' median APACHE II score was 14 (IQ: 11-22) and SOFA score was 9  
165 (IQ:7-10). The hospital mortality reached 62% and was higher than 28-day mortality which was  
166 53%. The patients who did not survive were significantly older (median 64 (IQ:52-70) vs. 50 (IQ:  
167 33-60) yrs.) and had higher APACHE II score in comparison to the survivors (20 (IQ:14-25) vs. 12  
168 (IQ:8-13)). Most common comorbidities were hypertension and cancer; however, their occurrence  
169 was not related with survival. The extra corporeal membrane oxygenation (ECMO) therapy was  
170 used in 29% of non-survivors and 18% of survivors. Twelve patients were admitted with co-  
171 infections with *Acinetobacter baumannii* and *Candida albicans* being the most common  
172 pathogens (3/12 each) followed by the methicillin-resistant *Staphylococcus aureus* (MRSA, 2/12).  
173 Twenty-one patients (47%) developed secondary infections with *A. baumannii* and *C. albicans* as  
174 the most frequent pathogens (6/21 each) followed by MRSA and *Stenotrophomonas maltophilia*  
175 (4/21 each).

176

177 **Markers of inflammasome activation are not outcome-related in  
178 critically ill COVID-19 patients**

179 Firstly, we have compared the levels of IL-1 $\alpha$ , IL-1 $\beta$ , IL-18, IL-1RA, galectin-1, ASC and  
180 gasdermin D in the study group with the age and sex matched group of traumatic brain injury  
181 (TBI) patients. Interestingly, only galectin-1 was significantly different in the critically ill COVID-19  
182 patients in comparison to TBI patients (17101.84 (IQ: 10836.62 - 25551.30) pg/ml vs. 30764.20  
183 (IQ: 23150.67 - 35759.48) pg/ml; p=0.007; **Fig. 1**). Then, we compared the concentration of the  
184 inflammasome related markers between COVID-19 survivors and non-survivors. Neither of the  
185 proteins could differentiate between these groups (**Fig. 2**). Moreover, LDH and ferritin which can  
186 serve as surrogate markers of cell death and IL-1 signaling, respectively, were not increased in  
187 patients with unfavorable outcome (**Tab. 2**). Other routinely monitored markers of inflammation as

188 white blood count, IL-6 or CRP were also similar in these two groups. Of the analyzed  
189 parameters, only the international normalized ratio (INR) was significantly higher in the non-  
190 surviving COVID-19 patients. However, logistic regression analysis did not reveal the relationship  
191 between INR either other analyzed parameters and mortality ( $p>0.05$ ). Also, there were no  
192 difference in the concentrations of the analyzed biomarkers of the inflammasome response  
193 between patients who were admitted with co-infections and those who were not. These results  
194 indicate that inflammasome-related proteins are less elevated in critically ill COVID-19 patients at  
195 ICU admission than in TBI patients and are not different between survivors and non-survivors.  
196

## 197 ***Galectin-1 and IL-1RA can stratify the severity of critically ill***

### 198 ***COVID-19 at the admission***

199 As the SOFA score is one of the most widely used tools to stratify the critically ill patients  
200 including COVID-19, we analyzed its predictive capacity in our group of patients. Indeed, the  
201 ROC analysis for in-hospital mortality was characterized by the area under the curve (AUC) of  
202 0.824 (95%CI: 0.703 - 0.944) which is of moderate accuracy <sup>15</sup>. As a predictor of death, the SOFA  
203 score of 9 points was characterized by the sensitivity of 75.0% and specificity of 64.7%. Then, we  
204 applied this cut-off point to divide the patients into two groups of high- and low-risk of death. The  
205 high-risk patients had significantly higher level of galectin-1 in comparison to individuals at low-  
206 risk (25551.30 (IQ: 15628.85 - 41048.02) pg/ml vs. 16302.72 (IQ: 8785.86 - 22040.25) pg/ml;  
207  $p=0.014$ , respectively). Interestingly, the high-risk group had significantly lower level of IL-1RA in  
208 comparison to the low-risk patients (14.50 (IQ: 9.28 - 47.01) vs. 39.35 (IQ: 17.87 - 88.01) pg/ml;  
209  $p=0.047$ ). The high-risk group patients were also characterized by higher white blood count  
210 (17.00 (IQ: 13.40 - 20.30)  $\times 10^6$ /ml vs. 12.75 (IQ: 10.20 - 16.80)  $\times 10^6$ /ml;  $p=0.034$ ), procalcitonin  
211 (2.10 (IQ: 0.40 - 4.00) ng/mL vs 0.25 (IQ: 0.11 - 0.60) ng/L;  $p=0.001$ ) and IL-6 (700.00 (IQ: 680.70  
212 - 1890.00) pg/ml vs. 66.60 (IQ: 16.00 - 107.00) pg/ml;  $p=0.001$ ). The frequency of co-infections  
213 was not significantly different between these groups, however chronic comorbidities such as  
214 coronary artery disease, heart failure and renal disease were significantly more common in the

215 high-risk patients. Of interest, patients who developed secondary infections had lower level of  
216 galectin-1 than those who did not (14908.51 (IQ: 8394.48 - 21,911.48) pg/ml vs. 23,839.62 (IQ:  
217 15,628.85 - 29,846.66) pg/ml; p=0.039, however logistic regression analysis did not confirm this  
218 relationship (OR=1.00, p=0.042). There were no differences among analyzed inflammasome-  
219 related biomarkers either standard inflammatory parameters (IL-6, PCT, WBC) between patients  
220 who developed secondary infections during ICU stay and those who did not. Altogether, these  
221 results suggest that the threshold of 9 SOFA score points indicated low- and high-risk critically ill  
222 COVID-19 patients who differed in the inflammasome and inflammatory profile.

223

224 ***Correlations of the inflammasome-related markers with other  
225 inflammatory markers in the critically ill COVID-19***

226 Additionally, we tested whether the concentrations of the inflammasome-related proteins are  
227 related with other measures. The Spearman's correlation test revealed a weak but significant  
228 correlation between IL-1 $\alpha$  and IL-1 $\beta$  ( $r=0.40$ ) and between IL-18 and IL-1RA ( $r=0.60$ ) and  
229 galectin-1 ( $r=0.27$ ). Gasdermin D correlated with the ASC protein ( $r=0.44$ ) and ferritin correlated  
230 with INR ( $r=0.39$ ) and LDH ( $r=0.45$ ). There was also inverse correlation between IL-1 $\alpha$  and  
231 platelets and IL-1 $\beta$  and platelets count ( $r=-0.37$  and  $r=-0.36$ , respectively). No significant  
232 correlations were found between the inflammasome-related markers and CRP, PCT, nor IL-6.  
233 These observations support the hypothesis that the plasma concentration of analyzed  
234 inflammasome-related proteins are concomitantly regulated and reflect the same cellular  
235 processes.

236 ***Cell free caspase-1 is not ubiquitously present in the  
237 circulation of critical COVID-19 patients***

238 As secretion of IL-1 and pyroptosis can result from the activation of other than inflammasome  
239 cellular pathways<sup>16</sup> we decided to confirm the activation of inflammasome in the COVID-19

240 patients by development of inhibitor-based immunoprecipitation of active caspase-1 followed by  
241 Western Blot detection of the specific fragments. Interestingly, the dominant form of caspase-1  
242 present in the plasma was the intermediate form p35 found in 12 of 22 COVID -19 patients (**Fig.**  
243 **3A**) while it was undetectable in TBI patients. In six of 22 COVID-19 patients also mature p20  
244 form could be detected (**Fig. 3A**). Presence of active caspase-1 was not related with outcome  
245 neither severity of the disease. There was also no difference in caspase-1 between patients with  
246 coinfections. However, patients at high-risk of death defined by SOFA score >9 had significantly  
247 higher amount of p35 in densitometric analysis (**Fig. 3B**) Of interest, patients with detectable p35  
248 had higher fibrinogen level (7.30 g/L (IQ: 5.50 - 8.70) vs. 5.45 g/L (IQ: 4.10 - 6.30); p=0.020) and  
249 lower d-dimers (1.35 µg/mL (IQ: 1.20 - 4.35) vs. 10.25 µg/mL (IQ: 6.30 - 20.90); p=0.019).

## 250 **Discussion**

251 Our study is the first to our best knowledge that have investigated comprehensively the  
252 plasma biomarkers related with inflammasome regulation in a well-defined group of critically ill  
253 COVID-19 patients at the ICU admission. We found that the marked activation of inflammasome  
254 defined as presence of active caspase-1 in the patient's plasma is not ubiquitous and not related  
255 with outcome. Also, other quantitative inflammasome-related proteins and cytokines are not  
256 related with outcome and only galectin-1 and IL-1RA differed in patients with low- and high-risk of  
257 death.

258 In this study we have focused on the critically ill COVID-19 patients at admission to ICU  
259 as this group is at high risk of death (reflected by 28-day mortality of 53% outreach by in-  
260 hospital mortality of 62% in our group). Although many groups have tried to identify new potential  
261 biomarkers, we have selected a panel of proteins related with different stages of the  
262 inflammasome activity. It included the structural component of inflammasome, the ASC protein;  
263 effector proteins cleaved by caspase-1 (IL-1 $\alpha$ , IL-1 $\beta$ , IL-18), their antagonist IL-1RA and  
264 gasdermin D which forms pyroptotic pores in cell membrane. Also, we measured galectin-1 and  
265 LDH which are markers of inflammatory cell death<sup>17</sup> and ferritin which is induced by the  
266 inflammasome activity<sup>18</sup>. Moreover, we have established a new method to analyze active

267 caspase-1 from human plasma which is based on the immunoprecipitation with biotinylated FAD-  
268 FMK, a pan-caspase inhibitor followed by Western Blot to specifically detected caspase-1 forms.

269 The concentration of the measures cytokines was not different between critical COVID-19  
270 and TBI patients. We choose the TBI patients for comparison as it relatively homogenous group  
271 with sterile injury, age- and sex-matched. ASC, IL-1 and caspase-1 were already shown to be  
272 upregulated in plasma of TBI patients <sup>19</sup>. Although increased galectin-1 was already described in  
273 COVID-19 patients <sup>20</sup> it was compared to healthy controls only. Here, we found higher galectin-1  
274 in TBI patients than COVID-19 which suggests that the latter is not characterized by extreme  
275 over-inflammatory response as suggested by some authors<sup>3,21</sup>. Our results expand the findings of  
276 others showing similar levels of inflammatory cytokines in COVID-19 and sepsis or other critical  
277 conditions <sup>22-24</sup>.

278 Neither of the analyzed protein was related with mortality in critically ill COVID-19  
279 patients. Although some of these cytokines like IL-18 or IL-1RA were already linked with the  
280 severity of COVID-19<sup>9,25,26</sup> it should be highlighted that our study is focused on a defined  
281 population of critical COVID-19 in contrast to most studies which compare cytokine levels in early  
282 COVID-19 of various severity. As the analyzed cytokines can be produced in inflammasome-  
283 independent manner, we assessed the presence of active caspase-1. We have detected the  
284 intermediate p35 form of caspase-1 in 54% cases and mature p20 in 27% patients. These finding  
285 clearly indicate that level of inflammasome activation is heterogenous in critical COVID-19 and  
286 complete maturation of caspase-1 is not common in these patients. The status of circulating  
287 caspase-1 was not related with outcome similarly to the findings by the group of D. Zamboni who  
288 utilized caspase-1 ELISA<sup>9</sup>. Even less frequently we were able to detect the ASC and GSDMD  
289 proteins which also indicates infrequent activation of inflammasome in critical COVID-19. Our  
290 results stay in accordance with recent findings that showed only small percentage of NLRP3 and  
291 AIM2 inflammasome activation in the circulating monocytes from COVID-19 patients<sup>10,27</sup>.  
292 Moreover, current data point at monocytes and macrophages as the major lung cell types  
293 showing activation of the inflammasome in COVID-19<sup>9,10</sup>. Additionally, we compared  
294 inflammasome-related proteins in the patients divided by their SOFA score at admission with the

295 most accurate threshold to predict mortality (low- and high-risk groups). Notably, galectin-1 and  
296 caspae-1 p35 was increased in the high-risk group, while IL-1RA was decreased. Such pattern  
297 may suggest indeed loss of control of this inflammatory pathway in the high-risk group of patients.  
298 The high-risk patients had also higher leukocyte count, IL-6, procalcitonin and INR however,  
299 neither of these parameters was significantly related with outcome in logistic regression model.

300 As inflammasomes are reported to play role in the susceptibility to secondary  
301 infections<sup>28,29</sup> we tested for the relation between inflammasome activation markers and co-  
302 infections or development of secondary infections however, there were no significant correlations  
303 between these variables. We observed some weak but significant correlations between IL-1 $\alpha$  and  
304 IL-1 $\beta$ , ASC and GSDMD, ferritin and LDH which suggests coordinated regulation of these  
305 mediators. Interestingly, we observed links between the inflammasome activity and dysregulated  
306 coagulation system. Patients with unfavorable prognosis had marks of coagulopathy indicated by  
307 higher INR values. In addition, there was a correlation between ferritin and INR and inversed  
308 correlation between IL-1 $\alpha$  and IL-1 $\beta$  and platelets. Altogether, these observations suggest  
309 mechanistic link between inflammasome activation and coagulopathy and possibly features of  
310 secondary hemophagocytic lymphohistiocytosis<sup>3</sup>.

311 This study has several limitations related with small patients' group and lack of  
312 mechanistic investigations. Noteworthy, our study group is well-defined and limited to the ARDS  
313 and sepsis forms of COVID-19. Although we analyzed several proteins related with activation of  
314 the inflammasome we did not measure other relevant mediators that can interact with this  
315 pathway (e.g. interferons). The present study would also benefit from the flow cytometry data of  
316 the inflammasome activation in circulating blood cells. Moreover, we analyzed only plasma  
317 proteins and it should be noted that they may not fully reflect the tissue response. Finally, we  
318 were not able to explain the heterogenic pattern of the inflammasome activity in these patients.

## 319 Conclusion

320 Our findings are of important clinical relevance as inflammasome-targeted therapies are  
321 widely testes in COVID-19, mostly without the use of biomarker guidance. Recently, the negative

322 results of the collaborative trial on the colchicine (which inhibits inflammasome formation<sup>30</sup>) were  
323 published<sup>31</sup>. Also, trials targeting IL-1 in severe COVID-19 with anakinra was reported to be  
324 negative<sup>14</sup>. At the same time, another study that used su-PAR levels to guide the anakinra  
325 treatment in early COVID-19 showed significant benefit<sup>13</sup>. The results of these studies are not  
326 surprising in the light of our findings showing heterogeneity in inflammasome activation in  
327 critically ill COVID-19 patients and lack of its direct relation with mortality. Yet, it could be  
328 speculated that in a selected subpopulation of patients with activated caspase-1 or high galectin-  
329 1 level these therapies could turn beneficial. Nevertheless, further mechanistic studies on the role  
330 of inflammasome in the pathogenesis of COVID-19 are needed.  
331

## 332 **Funding**

333 Study funded by the Polish National Science Centre grant no: UMO-2020/01/0/NZ6/00218  
334 (COVID-19) and by Wroclaw Medical University (Poland), grant number STM.A170.01.037.  
335

## 336 **Authors contribution**

337 All authors made substantial contributions to conception and design, acquisition of data, or  
338 analysis and interpretation of data; took part in drafting the article or revising it critically for  
339 important intellectual content; agreed to submit to the current journal; gave final approval of the  
340 version to be published; and agree to be accountable for all aspects of the work.

## 341 **Disclosure**

342 The author reports no conflicts of interest in this work.  
343  
344

## 345 References

- 346 1. <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>. Accessed  
347 19/10/2021  
348 , 2021.  
349 2. Armstrong RA, Kane AD, Kursumovic E, Oglesby FC, Cook TM. Mortality in patients  
350 admitted to intensive care with COVID-19: an updated systematic review and meta-  
351 analysis of observational studies. *Anaesthesia*. 2021;76(4):537-548.  
352 3. Osuchowski MF, Winkler MS, Skrecki T, et al. The COVID-19 puzzle: deciphering  
353 pathophysiology and phenotypes of a new disease entity. *Lancet Respir Med*.  
354 2021;9(6):622-642.  
355 4. Cavaillon JM, Singer M, Skrecki T. Sepsis therapies: learning from 30 years of failure of  
356 translational research to propose new leads. *EMBO Mol Med*. 2020;12(4):e10128.  
357 5. Osuchowski MF, Aletti F, Cavaillon JM, et al. SARS-CoV-2/COVID-19: Evolving Reality,  
358 Global Response, Knowledge Gaps, and Opportunities. *Shock*. 2020;54(4):416-437.  
359 6. Yap JKY, Moriyama M, Iwasaki A. Inflammasomes and Pyroptosis as Therapeutic  
360 Targets for COVID-19. *J Immunol*. 2020;205(2):307-312.  
361 7. Xue Y, Enosi Tuipulotu D, Tan WH, Kay C, Man SM. Emerging Activators and Regulators  
362 of Inflammasomes and Pyroptosis. *Trends Immunol*. 2019;40(11):1035-1052.  
363 8. Toldo S, Bussani R, Nuzzi V, et al. Inflammasome formation in the lungs of patients with  
364 fatal COVID-19. *Inflamm Res*. 2021;70(1):7-10.  
365 9. Rodrigues TS, de Sa KSG, Ishimoto AY, et al. Inflammasomes are activated in response  
366 to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. *J Exp  
367 Med*. 2021;218(3).  
368 10. Junqueira C, Crespo A, Ranjbar S, et al. SARS-CoV-2 infects blood monocytes to  
369 activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. *medRxiv*.  
370 2021.  
371 11. Ferreira AC, Soares VC, de Azevedo-Quintanilha IG, et al. SARS-CoV-2 engages  
372 inflammasome and pyroptosis in human primary monocytes. *Cell Death Discov*.  
373 2021;7(1):43.  
374 12. Herr C, Mang S, Mozafari B, et al. Distinct Patterns of Blood Cytokines Beyond a  
375 Cytokine Storm Predict Mortality in COVID-19. *J Inflamm Res*. 2021;14:4651-4667.  
376 13. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with  
377 anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-  
378 blind, randomized controlled phase 3 trial. *Nat Med*. 2021.  
379 14. Investigators TR-C, Derde LPG. Effectiveness of Tocilizumab, Sarilumab, and Anakinra  
380 for critically ill patients with COVID-19 The REMAP-CAP COVID-19 Immune Modulation  
381 Therapy Domain Randomized Clinical Trial. *medRxiv*. 2021;2021.2006.2018.21259133.  
382 15. Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of  
383 diagnostic test properties: clinical example of sepsis. *Intensive Care Med*.  
384 2003;29(7):1043-1051.  
385 16. Pyrillou K, Burzynski LC, Clarke MCH. Alternative Pathways of IL-1 Activation, and Its  
386 Role in Health and Disease. *Front Immunol*. 2020;11:613170.  
387 17. Russo AJ, Vasudevan SO, Mendez-Huergo SP, et al. Intracellular immune sensing  
388 promotes inflammation via gasdermin D-driven release of a lectin alarmin. *Nat Immunol*.  
389 2021;22(2):154-165.  
390 18. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. *Int Immunol*.  
391 2017;29(9):401-409.  
392 19. Kerr N, Lee SW, Perez-Barcena J, et al. Inflammasome proteins as biomarkers of  
393 traumatic brain injury. *PLoS One*. 2018;13(12):e0210128.  
394 20. Kazancioglu S, Yilmaz FM, Bastug A, et al. Assessment of Galectin-1, Galectin-3, and  
395 PGE2 Levels in Patients with COVID-19. *Jpn J Infect Dis*. 2021.  
396 21. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current  
397 Evidence and Treatment Strategies. *Front Immunol*. 2020;11:1708.

- 398 22. Wilson JG, Simpson LJ, Ferreira AM, et al. Cytokine profile in plasma of severe COVID-  
399 19 does not differ from ARDS and sepsis. *JCI Insight*. 2020;5(17).  
400 23. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine Levels in Critically  
401 III Patients With COVID-19 and Other Conditions. *JAMA*. 2020.  
402 24. Stolarski AE, Kim J, Zhang Q, Remick DG. Reply Letter to The Editor Regarding:  
403 Cytokine Drizzle-The Rationale for Abandoning The Term Cytokine Storm. *Shock*.  
404 2021;56(5):873-874.  
405 25. Satis H, Ozger HS, Aysert Yildiz P, et al. Prognostic value of interleukin-18 and its  
406 association with other inflammatory markers and disease severity in COVID-19. *Cytokine*.  
407 2021;137:155302.  
408 26. Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-  
409 10 with disease severity and RANTES with mild disease. *JCI Insight*. 2020;5(13).  
410 27. Courjon J, Dufies O, Robert A, et al. Heterogeneous NLRP3 inflammasome signature in  
411 circulating myeloid cells as a biomarker of COVID-19 severity. *Blood Adv*.  
412 2021;5(5):1523-1534.  
413 28. Roth S, Cao J, Singh V, et al. Post-injury immunosuppression and secondary infections  
414 are caused by an AIM2 inflammasome-driven signaling cascade. *Immunity*.  
415 2021;54(4):648-659 e648.  
416 29. Martinez-Garcia JJ, Martinez-Banaclocha H, Angosto-Bazarras D, et al. P2X7 receptor  
417 induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome  
418 activation during sepsis. *Nat Commun*. 2019;10(1):2711.  
419 30. Magupalli VG, Negro R, Tian Y, et al. HDAC6 mediates an aggresome-like mechanism  
420 for NLRP3 and pyrin inflammasome activation. *Science*. 2020;369(6510).  
421 31. Group RC. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a  
422 randomised, controlled, open-label, platform trial. *The Lancet Respiratory Medicine*.  
423 2021.  
424
- 425
- 426

427 **Table 1** Clinical and demographical characteristics of the critically ill COVID-19 patients

428

Characteristic	survivors (n=17)	non-survivors (n=28)	p
Age	50 (33-60)	64 (52-70)	<b>0.0030</b>
Sex (male), n (%)	8 (47)	16 (57)	0.1248
Hospitalization days	28 (13-45)	17 (7-28)	<b>0.0349</b>
ICU days	21 (6-35)	12 (4-18)	0.2508
28-day mortality	0	24	0.1336
SOFA score	7 (6-9)	9 (8-12)	0.0024
APACHE II score	12 (8-13)	20 (14-25)	<b>0.0001</b>
Comorbidities:			
Co-infections n (%)	3 (18)	9 (33)	0.4295
Cancer, n (%)	0 (0)	5 (18)	0.0773
Hypertension, n (%)	8 (47)	14 (50)	0.8482
Diabetes, n (%)	2 (12)	5 (18)	0.6931
Asthma, n (%)	1 (6)	3 (10)	1.0000
COPD, n (%)	0 (0)	1 (4)	1.0000
Obesity, n (%)	3 (18)	3 (10)	0.6581
Coronary artery disease, n (%)	0 (0)	4 (15)	0.2812
Chronic renal disease, n (%)	0 (0)	2 (7)	0.7029
Pregnancy, n (%)	3 (18)	0 (0)	<b>0.0160</b>
Secondary infections	9 (53)	12 (42)	0.7522

Treatment:			
CRRT, n (%)	0 (0)	6 (21)	0.1100
ECMO, n (%)	3 (18)	8 (29)	0.6390

429

430     **Abbreviations:** CCRT, continuous renal-replacement therapy; COPD, chronic obstructive  
431     pulmonary disease; ECMO, extra corporeal membrane oxygenation; ICU, intensive care unit;.

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453 **Table 2** Laboratory findings in the critically ill COVID-19 patients at the ICU admission


Characteristic	survivors (n=17)	non-survivors (n=28)	p
White blood count [ $\times 10^6/L$ ]	12.9 (10.8-15.5)	15.7 (11.6-18.9)	0.3736
Platelets [ $\times 10^9/L$ ]	287 (216-311)	241 (178-332)	0.2323
APTT [seconds]	33.1 (30.6-38.8)	36.0 (30.6-42.9)	0.3800
INR	1.10 (1.05-1.17)	1.24 (1.15-1.37)	<b>0.0095</b>
D-dimers [ug/ml]	1.80 (1.20-7.00)	6.45 (1.90-23.70)	0.0918
C-reactive protein [mg/L]	109.0 (67.0-149.0)	110.0 (67.5-195.0)	0.8149
Procalcitonin [ng/mL]	0.30 (0.11-0.43)	0.51 (0.14-1.95)	0.1528
Interleukin-6 [pg/ml]	75.85 (10.40-217.00)	88.80 (40.05-1001.50)	0.1939
Glucose [mg/dL]	136.0 (107.0-159.0)	172.5 (127.0-214.0)	0.1340
Ferritin [ng/ml]	698.5 (292.5-1563.5)	1156.0 (568.0-2002.0)	0.2089
Lactate dehydrogenase [U/L]	618.0 (480.0-709.0)	583.0 (427.0-930.0)	0.9906
Galectin-1 [pg/ml]	16424 (12957-22040)	21760 (10759-29643)	0.4329
IL-1 $\alpha$ [pg/ml]	4.80 (4.80-11.97)	5.46 (4.80-8.68)	0.9905
IL-1 $\beta$ [pg/ml]	7.39 (2.69-11.46)	8.08 (2.69-13.23)	0.9252
IL-1RA [pg/ml]	43.11 (17.87-68.17)	23.26 (10.71-87.75)	0.7519
IL-18 [pg/ml]	57.78 (41.11-94.15)	66.58 (24.14-96.61)	0.9160
ASC [pg/ml]	0.00 (0.00-0.00)	76.70 (18.70-134.700)	1.0000
GSDMD [pg/ml]	0.02 (0.02-0.27)	0.010 (0.06-0.12)	0.5509

454

455 **Abbreviations:** APTT, activated partial thromboplastin time; ASC, apoptosis-associated speck-like containing a CARD; GSDMD, gasdermin D.

457 **Figure 1. Comparison of the inflammasome-related markers in the traumatic brain injury**  
458 (**TBI**) and critical COVID-19 patients. A. Interleukin-1 $\alpha$ . B. Interleukin-1 $\beta$ . C. Interleukin-18.  
459 D. Interleukin-1 Receptor Antagonist. E. Apoptosis-associated speck-like protein containing a  
460 CARD. F. Gasdermin D. G. Galectin-1. Concentrations of plasma proteins were compared  
461 between TBI patients (n=10) with critically ill COVID-19 (n=45) with the Mann-Whitney test.  
462 \*\*p<0.05.

463



464

465


466

467

468

469

470 **Figure 2. Inflammasome-related markers in the plasma of critically ill COVID-19 patients at**  
471 **low- and high risk of death.** The high risk of death was stratified by the threshold of more than 9  
472 points in SOFA score. A. Interleukin-1 $\alpha$ . B. Interleukin-1 $\beta$ . C. Interleukin-18. D. Interleukin-1  
473 Receptor Antagonist. E. Apoptosis-associated speck-like protein containing a CARD. F.  
474 Gasdermin D. G. Galectin-1. H. Lactate Dehydrogenase. I. Ferritin. Concentrations of plasma  
475 proteins were compared between patients at high risk (n=15) with patients at low risk of death  
476 (n=30) with the Mann-Whitney test. \*p<0.05.




477  
478  
479  
480  
481  
482  
483


484 **Figure 3. Active caspase-1 is unambiguously present in critical COVID-19 patient's plasma.**

485 A. Representative immunoblots with labeled with anti-caspase-1 of the pull-downed FAD-FMK  
486 bonded caspases from the plasma of TBI patients (3TBI, 5 TBI) and COVID-19 patients (numbers  
487 8-22). The mature p20 band is present in approx. half of the patients with intermediate p35 form.  
488 B. Patients at high risk of death (SOFA>9) had more circulating p35 as revealed by densitometric  
489 analysis. Data were compared with the Mann-Whitney test. \*p<0.05.

A



B



490

491

492